Pharmacodynamics<unk>  is a GnRH agonist, or an agonist of the GnRH receptor, the biological target of GnRH. It works by continuously activating the GnRH receptor, which results in profound desensitization of the receptor such that it becomes non-functional. As a result,<unk>  suppresses the GnRH-induced secretion of the gonadotropins, luteinizing hormone and follicle-stimulating hormone, from the pituitary gland. This, in turn, results in profound suppression of gonadal sex hormone production, as well as reversible suppression of fertility. Pharmacokinetics The bioavailability of<unk>  with intranasal administration is 2.8% on average, with a range of 1.2 to 5.6%. The plasma protein binding of<unk>  is 80%. It is metabolized primarily by peptidases and not by cytochrome P450 enzymes. The elimination half-life of<unk>  is 2.5 to 3.0 hours by intranasal administration, whereas the half-life of<unk>  and its metabolites by subcutaneous injection is 85.5 hours.<unk>  is eliminated 44 to 55% in urine and 18.5 to 44.2% in feces.
Nafarelin
Protollin
Macimorelin
Dienogest
Tesamorelin
Degarelix
Ingenol mebutate
Tolbutamide